cetrorelix: Clinical Trials

17 trials of cetrorelix, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 3 unknown, 1 not yet recruiting, 1 recruiting. 17 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 317Completed 11, Unknown 3, Not yet recruiting 1, Recruiting 1, Terminated 1
Phase 22Completed 1, Unknown 1

Follow cetrorelix: new trials by email Literature Review of cetrorelix trials Research Report on cetrorelix

Trials (filtered) newest first · largest first

All 17 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A
GnRH antagonist, MPA - Preimplantation Genetic Testing, Progestin-primed Ovarian Stimulation
Phase 3Not yet recruitingShangHai Ji Ai Genetics & IVF Institute2042027-06-012026-11-09
A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)
Follitropin alfa/lutropin alfa (MBJ-0011), hMG, Cetrorelix acetate - Infertility
Phase 3RecruitingMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany2662026-02-052026-10-29
Progesterone Primed Protocol Versus GnRH Antagonist in With PCO Undergoing ICSI
Dydrogesterone Tablets, Cetrorelix - IVF, PCO
Phase 2 / Phase 3CompletedBeni-Suef University2002024-01-012026-04-15
Dydrogesterone, Cetrorelix Acetate and Triptorelin in Intra Cytoplasmic Sperm Injection Outcomes
Dydrogesterone, Cetrorelix acetate, Triptorelin - IVF
Phase 3UnknownBeni-Suef University3872023-07-152023-08-02
PPOS Protocol Versus GnRH Anatagonist for Expected Normal Responder Patients Undergoing ART : a Randomized Clinical Trial
Dydrogesterone Oral Tablet, Cetrorelix (Cetrotide) - PPOS, GnRH Antagonist
Phase 3CompletedKasr El Aini Hospital3282023-01-032025-03-11
Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A
GnRH antagonist, oral Duphaston - Preimplantation Genetic Testing, Progestin-primed Ovarian Stimulation
Phase 3CompletedShangHai Ji Ai Genetics & IVF Institute4002020-06-102025-05-31
Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response
Progesterone, GnRH Antagonist - IVF, GnRH Antagonist
Phase 3CompletedShangHai Ji Ai Genetics & IVF Institute7842020-06-042023-08-30
Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)
FE 999049 + GnRH agonist (GONAPEPTYL), FE 999049 + GnRH antagonist (CETROTIDE) - Infertility, Female
Phase 3CompletedFerring Pharmaceuticals4372019-04-292024-05-13
Delayed Start Versus Conventional Antagonist Protocol in Poor Responders Pretreated by Estradiol in Luteal Phase
cetrotide - Other Complications Associated With Artificial Fertilization
Phase 3CompletedCairo University602015-01-012016-01-27
Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome
Cetrorelix - Infertility
Phase 2 / Phase 3UnknownBenha University482014-10-012017-03-30
Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS)
degarelix (long acting GnRH antagonist), cetrorelix 0.25mg - PCOS, OHSS
Phase 3CompletedCentre for Endocrinology and Reproductive Medicine, Italy802012-11-012016-04-27
The Results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of Embryos Obtained From GnRH-agonist Long and GnRH-antagonist Ovarian Stimulation Protocol
ghrh antagonist (cetrotide/orgalutran), gnrh agonist (suprefact) - Embryo's Genetic and Chromosomal Quality
Phase 3UnknownEuropean Hospital2002012-09-012012-07-10
GnRH Antagonist for Treatment of Early Ovarian Hyperstimulation Syndrome
GnRH antagonist (Cetrorelix), Placebo (saline solution) - Ovarian Hyperstimulation Syndrome, Effects of Gonadotropin
Phase 3CompletedInstituto Valenciano de Infertilidad, IVI VALENCIA1002012-04-012013-09-19
GnRH Antagonist Versus GnRH Agonist in Polycystic Ovary Syndrome During in Vitro Fertilization - Embryo Transfer
GnRH antagonist (Cetrorelix), Conventional GnRH agonist (Triptorelin) - Infertility, Polycystic Ovary Syndrome
Phase 3CompletedSeoul National University Hospital432011-06-012017-10-10
Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)
Cetrorelix acetate, Recombinant Human Choriogonadotropin (r-hCG), Recombinant human follicle stimulating hormone (r-hFSH) - Polycystic Ovarian Syndrome
Phase 3CompletedMerck KGaA, Darmstadt, Germany1362008-11-012014-02-13
Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)
Cetrorelix Pamoate - Benign Prostatic Hypertrophy
Phase 3CompletedAEterna Zentaris5282008-03-012011-04-05
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Cetrorelix 78 mg + 78 mg, Cetrorelix 78 mg + 52 mg, Placebo - Benign Prostatic Hypertrophy
Phase 3TerminatedAEterna Zentaris6672007-03-012018-08-03

Conditions studied

Infertility (4)  ·  Polycystic Ovary Syndrome (3)  ·  Prostatic Hyperplasia (2)  ·  Infertility, Female (1)  ·  Ovarian Hyperstimulation Syndrome (1)

Sponsors

ShangHai Ji Ai Genetics & IVF Institute (3)  ·  AEterna Zentaris (2)  ·  Beni-Suef University (2)  ·  Benha University (1)  ·  Cairo University (1)  ·  Centre for Endocrinology and Reproductive Medicine, Italy (1)  ·  European Hospital (1)  ·  Ferring Pharmaceuticals (1)  ·  Instituto Valenciano de Infertilidad, IVI VALENCIA (1)  ·  Kasr El Aini Hospital (1)  ·  Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1)  ·  Merck KGaA, Darmstadt, Germany (1)  ·  Seoul National University Hospital (1)

Countries

Egypt (5)  ·  Italy (3)  ·  Canada (2)  ·  China (2)  ·  United States (2)  ·  Austria (1)  ·  Bulgaria (1)  ·  Denmark (1)  ·  France (1)  ·  Germany (1)  ·  Israel (1)  ·  Japan (1)  ·  Netherlands (1)  ·  Norway (1)  ·  South Korea (1)

Top investigators

Ahmed M Maged, MD (1)  ·  Dr. Hebert Lepor, MD (1)  ·  Juan Giles, MD (1)  ·  Marco Sbracia, MD (1)  ·  Young Min Choi, M.D., Ph.D. (1)

Results publications

PMID 22197127, PMID 29132339, PMID 38272383, PMID 38521533, PMID 38723189, PMID 42819751

NIH funding

2017 (1)